You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 118 No. 6, June 1983 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on Web of Science (15)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Cyclosporine in Treatment of Corticosteroid-Resistant Episodes of Rejection

Pekka Häyry, MD; Eeva von Willebrand, MD; Eero Taskinen, MD; Juhani Ahonen, MD; Björn Eklund, MD; Krister Höckerstedt, MD; Erna Petterson, MD; Hans Sarelin, MA

Arch Surg. 1983;118(6):750-755.


Abstract

• We used cyclosporine (formerly called cyclosporin A) to treat established episodes of kidney-transplant rejection in six patients in whom the use of corticosteroids either was ineffective or was precluded by preestablished side effects. All patients were followed up by using fine-needle aspiration biopsy and transplant aspiration cytology. In four episodes of rejection with typical blast cell-dominated inflammation, the response to cyclosporine was apparently favorable: the inflammatory cells disappeared within days and the transplant resumed its normal function. One episode of acute rejection was overcome within a week after discontinuing treatment with cyclosporine. In one episode of chronic rejection that was devoid of any distinct blastogenic component, no effect of cyclosporine could be detected. We believe that cyclosporine can be used to treat established episodes of rejection, but what type or types of inflammatory episodes are susceptible to cyclosporine must first be clarified through prerandomized clinical trials.

(Arch Surg 1983;118:750-755)



Author Affiliations

From the Transplantation Laboratory (Drs Häyry, Willebrand, and Taskinen) and Fourth Department of Surgery (Drs Häyry, Eklund, Höckerstedt, and Petterson), University of Helsinki, and Sandoz Pharmaceuticals, Ltd (Mr Sarelin), Helsinki.


Footnotes

Accepted for publication Aug 9, 1982.

Reprint requests to Transplantation Laboratory, University of Helsinki, Haartmaninkatu 3, SF 00290 Helsinki 29, Finland (Dr Häyry).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1983 American Medical Association. All Rights Reserved.